Q3-osavuosiraportti
16 päivää sitten‧45 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
162 339
Myynti
Määrä
159 671
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 148 183 | ENS | ENS | ||
| 25 000 | DDB | DDB | ||
| 826 | - | - | ||
| 222 | - | - | ||
| 2 811 | - | - |
Ylin
186,35VWAP
Alin
184,65VaihtoMäärä
101,4 548 007
VWAP
Ylin
186,35Alin
184,65VaihtoMäärä
101,4 548 007
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 14.11. | |
| 2025 Q2-osavuosiraportti | 26.8. | |
| 2025 Q2-osavuosiraportti | 22.8. | |
| 2025 Q1-osavuosiraportti | 9.5. | |
| 2024 Yhtiökokous | 9.4. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenHopefully BAVA will choose to initiate a buyback program and use some of their lovely voucher millions to please the shareholders now that management is in bad standing with many shareholders :) One can always hope :) Have a good weekend.
·1 päivä sittenBava has a goal of becoming the world's leading vaccine company. This will require a number of acquisitions (considering their not particularly large pipeline) and that was one of the arguments for the board supporting the takeover bid: The private equity funds claimed that they would inject enough capital into the company to be able to realize the plans. As is known, the offer fell through, so now Bava must execute the strategy with its own funds or change strategy. This was the strategy long before the takeover bid, so the fact that an offer has come and gone hardly changes much here, so my guess is that they will stick to the strategy unless the shareholders tell them it needs to be changed or things happen around them that make the strategy no longer make sense. If they stick to it, the amount of capital Bava has left over for distributions or buybacks in the coming years will be limited. Instead, we must bet on the acquisitions adding value and pushing up the share price over time. This is certainly quite conceivable: There are synergies in both production, sales, and distribution, and generally, vaccine companies do not trade particularly expensively. At the same time, Bava has demonstrated that they are quite good at this discipline (if one disregards the unfortunate timing of buying a portfolio of travel vaccines in 2019 before anyone knew that the next years would be characterized by a pandemic). But that is not a guarantee that it will also go well next time.
·1 päivä sittenShit, you are naive. That was their "goal" which they themselves didn't believe in and tried to sell the business. If heads don't roll at the top soon, then it will go under 100 within 2 years.
·1 päivä sittenThe stock is currently around 185 DKK, and analysts consider it undervalued with a price target of approx. 250 DKK. If a new epidemic were to break out, it could potentially be an advantage for Bavarian Nordic, as the company specializes in vaccines and has a strong pipeline. But the board, I still think is a big?
·2 päivää sittenBesides a new chairman for the board - is everything still as before at the company - without further changes...? The chairman was, after all, also previously a member of the board. What do you think?
·2 päivää sittenLooking forward to the investor meeting on 11/12, maybe there's an underlying reason for holding it. Maybe a rabbit 🐰 out of the hat??
·2 päivää sittenI don't think any rabbits will be pulled out of the hat at what looks like a closed meeting without a live stream and with a very limited number of chairs for attendance. If any rabbits are pulled out, it will be announced via a PR when the time is right...
·3 päivää sitten · MuokattuWill we see 200 before we go into the weekend :) :) And maybe 250 before the turn of the year :) :) That would be so nice with a small Christmas upward adjustment :) Then those funds can indeed run and jump :) :)·3 päivää sittenThe company has lowered its guidance 2 times in 2025 and is balancing on the 3rd guidance cut. From where do you think there is a probability of an upward adjustment?- ·25.11.What are the thoughts on the price from here? Is it perhaps worth buying?😉
·1 päivä sittenFundamentally, I don't think you can count your chickens before they hatch.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
16 päivää sitten‧45 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenHopefully BAVA will choose to initiate a buyback program and use some of their lovely voucher millions to please the shareholders now that management is in bad standing with many shareholders :) One can always hope :) Have a good weekend.·1 päivä sittenBava has a goal of becoming the world's leading vaccine company. This will require a number of acquisitions (considering their not particularly large pipeline) and that was one of the arguments for the board supporting the takeover bid: The private equity funds claimed that they would inject enough capital into the company to be able to realize the plans. As is known, the offer fell through, so now Bava must execute the strategy with its own funds or change strategy. This was the strategy long before the takeover bid, so the fact that an offer has come and gone hardly changes much here, so my guess is that they will stick to the strategy unless the shareholders tell them it needs to be changed or things happen around them that make the strategy no longer make sense. If they stick to it, the amount of capital Bava has left over for distributions or buybacks in the coming years will be limited. Instead, we must bet on the acquisitions adding value and pushing up the share price over time. This is certainly quite conceivable: There are synergies in both production, sales, and distribution, and generally, vaccine companies do not trade particularly expensively. At the same time, Bava has demonstrated that they are quite good at this discipline (if one disregards the unfortunate timing of buying a portfolio of travel vaccines in 2019 before anyone knew that the next years would be characterized by a pandemic). But that is not a guarantee that it will also go well next time.·1 päivä sittenShit, you are naive. That was their "goal" which they themselves didn't believe in and tried to sell the business. If heads don't roll at the top soon, then it will go under 100 within 2 years.
- ·1 päivä sittenThe stock is currently around 185 DKK, and analysts consider it undervalued with a price target of approx. 250 DKK. If a new epidemic were to break out, it could potentially be an advantage for Bavarian Nordic, as the company specializes in vaccines and has a strong pipeline. But the board, I still think is a big?
- ·2 päivää sittenBesides a new chairman for the board - is everything still as before at the company - without further changes...? The chairman was, after all, also previously a member of the board. What do you think?·2 päivää sittenLooking forward to the investor meeting on 11/12, maybe there's an underlying reason for holding it. Maybe a rabbit 🐰 out of the hat??·2 päivää sittenI don't think any rabbits will be pulled out of the hat at what looks like a closed meeting without a live stream and with a very limited number of chairs for attendance. If any rabbits are pulled out, it will be announced via a PR when the time is right...
- ·3 päivää sitten · MuokattuWill we see 200 before we go into the weekend :) :) And maybe 250 before the turn of the year :) :) That would be so nice with a small Christmas upward adjustment :) Then those funds can indeed run and jump :) :)·3 päivää sittenThe company has lowered its guidance 2 times in 2025 and is balancing on the 3rd guidance cut. From where do you think there is a probability of an upward adjustment?
- ·25.11.What are the thoughts on the price from here? Is it perhaps worth buying?😉·1 päivä sittenFundamentally, I don't think you can count your chickens before they hatch.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
162 339
Myynti
Määrä
159 671
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 148 183 | ENS | ENS | ||
| 25 000 | DDB | DDB | ||
| 826 | - | - | ||
| 222 | - | - | ||
| 2 811 | - | - |
Ylin
186,35VWAP
Alin
184,65VaihtoMäärä
101,4 548 007
VWAP
Ylin
186,35Alin
184,65VaihtoMäärä
101,4 548 007
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 14.11. | |
| 2025 Q2-osavuosiraportti | 26.8. | |
| 2025 Q2-osavuosiraportti | 22.8. | |
| 2025 Q1-osavuosiraportti | 9.5. | |
| 2024 Yhtiökokous | 9.4. |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
16 päivää sitten‧45 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 14.11. | |
| 2025 Q2-osavuosiraportti | 26.8. | |
| 2025 Q2-osavuosiraportti | 22.8. | |
| 2025 Q1-osavuosiraportti | 9.5. | |
| 2024 Yhtiökokous | 9.4. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenHopefully BAVA will choose to initiate a buyback program and use some of their lovely voucher millions to please the shareholders now that management is in bad standing with many shareholders :) One can always hope :) Have a good weekend.·1 päivä sittenBava has a goal of becoming the world's leading vaccine company. This will require a number of acquisitions (considering their not particularly large pipeline) and that was one of the arguments for the board supporting the takeover bid: The private equity funds claimed that they would inject enough capital into the company to be able to realize the plans. As is known, the offer fell through, so now Bava must execute the strategy with its own funds or change strategy. This was the strategy long before the takeover bid, so the fact that an offer has come and gone hardly changes much here, so my guess is that they will stick to the strategy unless the shareholders tell them it needs to be changed or things happen around them that make the strategy no longer make sense. If they stick to it, the amount of capital Bava has left over for distributions or buybacks in the coming years will be limited. Instead, we must bet on the acquisitions adding value and pushing up the share price over time. This is certainly quite conceivable: There are synergies in both production, sales, and distribution, and generally, vaccine companies do not trade particularly expensively. At the same time, Bava has demonstrated that they are quite good at this discipline (if one disregards the unfortunate timing of buying a portfolio of travel vaccines in 2019 before anyone knew that the next years would be characterized by a pandemic). But that is not a guarantee that it will also go well next time.·1 päivä sittenShit, you are naive. That was their "goal" which they themselves didn't believe in and tried to sell the business. If heads don't roll at the top soon, then it will go under 100 within 2 years.
- ·1 päivä sittenThe stock is currently around 185 DKK, and analysts consider it undervalued with a price target of approx. 250 DKK. If a new epidemic were to break out, it could potentially be an advantage for Bavarian Nordic, as the company specializes in vaccines and has a strong pipeline. But the board, I still think is a big?
- ·2 päivää sittenBesides a new chairman for the board - is everything still as before at the company - without further changes...? The chairman was, after all, also previously a member of the board. What do you think?·2 päivää sittenLooking forward to the investor meeting on 11/12, maybe there's an underlying reason for holding it. Maybe a rabbit 🐰 out of the hat??·2 päivää sittenI don't think any rabbits will be pulled out of the hat at what looks like a closed meeting without a live stream and with a very limited number of chairs for attendance. If any rabbits are pulled out, it will be announced via a PR when the time is right...
- ·3 päivää sitten · MuokattuWill we see 200 before we go into the weekend :) :) And maybe 250 before the turn of the year :) :) That would be so nice with a small Christmas upward adjustment :) Then those funds can indeed run and jump :) :)·3 päivää sittenThe company has lowered its guidance 2 times in 2025 and is balancing on the 3rd guidance cut. From where do you think there is a probability of an upward adjustment?
- ·25.11.What are the thoughts on the price from here? Is it perhaps worth buying?😉·1 päivä sittenFundamentally, I don't think you can count your chickens before they hatch.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
162 339
Myynti
Määrä
159 671
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 148 183 | ENS | ENS | ||
| 25 000 | DDB | DDB | ||
| 826 | - | - | ||
| 222 | - | - | ||
| 2 811 | - | - |
Ylin
186,35VWAP
Alin
184,65VaihtoMäärä
101,4 548 007
VWAP
Ylin
186,35Alin
184,65VaihtoMäärä
101,4 548 007
Välittäjätilasto
Dataa ei löytynyt